0000000000726969

AUTHOR

Laurence Moore

showing 2 related works from this author

Changes from 1986 to 2006 in reasons for liking leisure-time physical activity among adolescents

2016

Reasons for participating in physical activity (PA) may have changed in accordance with the general modernization of society. The aim is to examine changes in self-reported reasons for liking leisure-time physical activity (LTPA) and their association with self-reported LTPA over a 20-year period. Data were collected among nationally representative samples of 13-year-olds in Finland, Norway, and Wales in 1986 and 2006 (N = 9252) as part of the WHO cross-national Health Behaviour in School-aged Children (HBSC) study. Univariate ANOVAs to establish differences according to gender, year, and country were conducted. In all countries, 13-year-olds in 2006 tended to report higher importance in te…

MaletrendsHealth Knowledge Attitudes PracticePediatricsmedicine.medical_specialtyAdolescentHealth BehaviorPsychological interventionPoison controlPhysical Therapy Sports Therapy and RehabilitationSuicide preventionOccupational safety and healthyoung people03 medical and health sciencesLeisure Activities0302 clinical medicinenuoretmotivationSurveys and QuestionnairesInjury preventionmedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineta315ExerciseFinlandAnalysis of VarianceWalesNorwaybusiness.industry030229 sport sciencesta3142AchievementSocial ParticipationSocial engagementSport psychologytrenditsport psychologyliikuntapsykologiaH1FemaleHealth educationYoung peoplebusinesshuman activitiesDemographymodernizationScandinavian Journal of Medicine and Science in Sports
researchProduct

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009

Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease. Patients and Methods In this multicenter, open-label, phase III study, 162 patients with relapsed or refractory MCL were randomly assigned (1:1:1) to receive one of two temsirolimus regimens: 175 mg weekly for 3 weeks followed by either 75 mg (175/75-mg) or 25 mg (175/25-mg) weekly, or investigator's choice therapy from prospectively approved options. The primary end point was progression-free survival (P…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAntineoplastic AgentsKaplan-Meier EstimateLymphoma Mantle-CellDisease-Free SurvivalDrug Administration ScheduleRidaforolimuschemistry.chemical_compoundRefractoryRecurrenceInternal medicinemedicineHumansProspective StudiesProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryLymphoma Non-HodgkinTOR Serine-Threonine KinasesMiddle Agedmedicine.diseaseTemsirolimusSurgeryFludarabineOncologychemistryDrug Resistance NeoplasmSirolimusRefractory Mantle Cell LymphomaFemaleRituximabMantle cell lymphomabusinessProtein Kinasesmedicine.drugJournal of Clinical Oncology
researchProduct